Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.06
-0.08 (-1.30%)
Sep 18, 2024, 4:00 PM EDT - Market closed
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $3.43M in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to $9.55M. In the year 2023, Coya Therapeutics had annual revenue of $6.00M.
Revenue (ttm)
$9.55M
Revenue Growth
n/a
P/S Ratio
7.99
Revenue / Employee
$1,194,289
Employees
8
Market Cap
92.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCOYA News
- 2 days ago - Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson's Disease - Business Wire
- 15 days ago - Coya Therapeutics to Present at Upcoming Healthcare Conferences - Business Wire
- 4 weeks ago - Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - Business Wire
- 5 weeks ago - Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - Business Wire
- 6 weeks ago - Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid - Business Wire
- 7 weeks ago - Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - Business Wire
- 3 months ago - Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic - Business Wire
- 3 months ago - Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology - Business Wire